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Abstract
Background: Gastro-Esophageal Reflux Disease (GERD) defined as a condition that develops when the reflux of
stomach contents causes troublesome symptoms and/or complications. Many drugs are used for the treatment of
GERD such as omeprazole (a proton pump inhibitor) which is a widely used antiulcer drug demonstrated to
protect against esophageal mucosal injury. Melatonin has been found to protect the gastrointestinal mucosa from
oxidative damage caused by reactive oxygen species in different experimental ulcer models. The aim of this study
is to evaluate the role of exogenous melatonin in the treatment of reflux disease in humans either alone or in
combination with omeprazole therapy.
Methods: 36 persons were divided into 4 groups (control subjects, patients with reflux disease treated with
melatonin alone, omeprazole alone and a combination of melatonin and omeprazole for 4 and 8 weeks) Each
group consisted of 9 persons. Persons were subjected to thorough history taking, clinical examination, and
investigations including laboratory, endoscopic, record of esophageal motility, pH-metry, basal acid output and
serum gastrin.
Results: Melatonin has a role in the improvement of Gastro-esophageal reflux disease when used alone or in
combination with omeprazole. Meanwhile, omeprazole alone is better used in the treatment of GERD than
melatonin alone.
Conclusion: The present study showed that oral melatonin is a promising therapeutic agent for the treatment of
GERD. It is an effective line of treatment in relieving epigastric pain and heartburn. However, further studies are
required to confirm the efficacy and long-term safety of melatonin before being recommended for routine clinical
use.
Trial Registration: QA13NCT00915616
Background
Gastro esophageal reflux Disease (GERD) is defined as a
condition that develops when the reflux of stomach con-
tents causes troublesome symptoms and/or complica-
tions [1]. Symptoms of GERD occur in approximately
14 to 20% of the population on at least a weekly basis.
Symptoms of GERD may result in a large burden on
employers through increased absenteeism and decreased
performance while remaining at work impaired by
health problems [2].
Even though over 50 years have passed since the dis-
covery of melatonin, the knowledge on its physiological
function is still not complete. The results of the
researches have provided the evidence that melatonin is
synthesized not only in the pineal gland, but also in dif-
ferent organs. A special attention has been directed to
the digestive tract where total quantity of melatonin is
considerably greater than in the pineal gland [3]. It was
calculated that the gastrointestinal tract contains at least
400 times melatonin than the pineal gland [4]. Although
pineal melatonin acts prevalently in an endocrine capa-
city, extra-pineal melatonin may act as an autocrine or a
paracrine hormone [5]. It protects gastric mucosa
against destructive activity of free radicals in stress-
induced ulcers and due to non-steroidal anti-inflamma-
tory drugs and other gastrotoxic agents [6]. Further-
more, Kato et al. [7] demonstrated the inhibitory action
of melatonin on secretion of HCL and pepsin. Only a
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been carried out on humans.
In view of melatonin’s known gut regulatory functions,
antidepressant and anxiolytic properties, and its poten-
tially beneficial effects on brain gut axis, it was hypothe-
sized that melatonin might serve as an effective agent
for treating GERD.
Methods
Sixty subjects “60”, suffering from GERD symptoms,
were attending the outpatient clinics of the Gastro-
Enterology Center and Specialized Medical Hospital.
Informed consent was obtained from all patients to be
included in the study, after explanations of the nature of
the disease and treatment options. All patients signed
an informed consent to be included in our study. This
paper was approved by the local ethical committee of
Mansoura University Hospital, General Surgery
Department.
All individuals were subjected to thorough history tak-
ing including: history of drug intake, epigastric pain,
upper gastrointestinal bleeding (hematemesis and/or
melena), dyspeptic manifestations and heartburn. They
were also subjected to clinical examination with special
stress on: (a) General examination: pulse, blood pressure
and temperature. (b) Chest and heart examination. (c)
Local abdominal examination for the state of the liver,
spleen and the presence or absence of ascites. They also
underwent laboratory investigations:C o m p l e t eb l o o d
picture, Urine and stool analysis and Liver function tests
including serum albumin, bilirubin, alanine transaminase
enzyme (ALT), aspartate transaminase enzyme (AST).
The patients excluded from our study were; patients
with cardiac disease, patients with renal affection, and
patients with liver diseases (drug induced, autoimmune
disease and viral hepatitis). In addition, patients on the
drugs known to affect the GIT motility (phenothiazines,
anticholinergics, nitrates or calcium channel blockers)
excluded during the time of conduction of the study or
the preceding two weeks. After exclusion, 45 subjects
were selected for evaluation by: a) Endoscopic Investiga-
tion: subjects were subjected to upper gastrointestinal
endoscopy for visualization of the mucosa of esophagus
and stomach for the presence of mucosal ulceration. b)
Record of esophageal motility by Smart graph analysis
software lab motility system Sandhill 8 - channels eso-
phageal manometry. Manometric recording systems rely
on computers for data acquisition display and analysis.
This manometric recording was done by using station
pull through technique at 5 minutes intervals. The most
important aspect of Lower Esophageal Sphincter (LES)
pressure measurement is that of LES relaxation. Subjects
with duodenal, gastric ulcers or functional dyspepsia
were excluded and finally 27 subjects with GERD were
selected to complete the study compared with nine
healthy volunteers who matched with age and sex as
controls or reference.
After admission the following was done: (a) blood
samples for measuring serum melatonin levels taken at
10.00 p.m., 2.00 a.m. and 6.00 a.m. After collecting the
sample, the blood centrifuged and serum thus was
obtained and frozen at the temperature of minus 80°C.
Melatonin concentration was measured with ELISA
method using the Lab system Multiscan and antibodies
of the Immuno-Biological Laboratories (catalogue RE
54021) [8]. (b)An ambulatory digitrapper was used to
perform 24 hours pH-metry measurement by UP S2020
Orion MMS Holland pH-metry. The pH probe was
positioned 5 cm above the position of the LES. The data
were collected using De-meester (DM) score; gastroeso-
phageal reflux considered as a drop in esophageal PH
below “4” and the percentage reflux in 24 hours calcu-
lated for each patient [9].
Basal Acid Output (BAO)
At the end of each pH-metry monitoring period, the
electrode was removed and BAO was measured during
o n eh o u rt h r o u g han a s o - g a s t r i ct u b ei n s e r t e da tt h e
most dependent part of the stomach. The correct posi-
tion of the tube was checked by the water recovery test.
Patients were laid in a semi-recumbent position on their
left side. Gastric secretion was aspirated continuously by
gentle manual suction and collected in 15-minute sam-
ples after discarding the first 15-minute collection corre-
sponding to the emptying of the stomach. The
concentration of H
+ ions was determined on each sam-
p l eb yat i t r i m e t r i cm e t h o dw i t hN a O H0 . 1 Na n d
expressed in millimoles H
+ per litre. BAO is the sum of
the four 15-minute outputs and is expressed in mmol H
+/h.
Determination of serum gastrin levels
The serum gastrin concentration was measured by a
radioimmunoassay method using C-terminal-directed
antibodies equally reactive to little gastrins (G-17) and
big gastrins G-34. Serum Gastrin was expressed in pico-
grams per milliliter.
Groups: The subjects selected were classified into four
groups: Group I included nine healthy normal subjects
and was considered the control group. Group II
included nine patients suffering from GERD; receiving
melatonin alone for treatment of GERD in a dose of 3
mg once daily at the bedtime [10]. Group III included
nine patients suffering from GERD, receiving omepra-
zole alone for treatment of GERD in a dose of 20 mg
twice daily [11]. Group IV included nine patients suffer-
ing from GERD receiving omeprazole and melatonin for
treatment of GERD in the same dose of each of them.
The three patient groups were re-evaluated after 4
weeks and 8 weeks of treatment.
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The statistical analysis was performed using the SPSS
statistical Package version 13.0 (SPSS, Chicago, IL,
USA). To compare the data, the recorded values were
expressed as means and standard deviation (Mean ±
SD). The minimal level of significance was identified at
p < 0.05 [12].
Results
Table 1 illustrates that pretreated Patients with
GERD showed heartburn, epigastric pain, and signifi-
cant decrease in LES pressure, residual pressure,
relaxation percentage, pH, serum gastrin and mean
melatonin level and a significant increase in relaxa-
tion duration and basal acid output (BAO) relative to
control group.
Table 2 illustrates that treatment with melatonin for 4
and 8 weeks leads to marked improvement of GERD
symptoms regarding heartburn and epigastric pain.
There was also a significant increase in the tone of the
LES in the form of increased LES pressure, a significant
increase in the residual pressure, a significant decrease
in the relaxation duration, a significant increase in the
relaxation percentage, a significant increase in the pH
with a significant decrease in BAO, and a significant
increase in serum gastrin and mean melatonin levels
relative to pretreated patients.
Table 3 illustrates that treatment with omeprazole for
4 and 8 weeks leads to marked improvement of GERD
symptoms regarding heartburn and epigastric pain.
There was also a non-significant change in the tone of
the LES, a non-significant change in the residual pres-
sure, relaxation duration, relaxation percentage, a signifi-
cant increase in the pH with a significant decrease in
BAO, a significant increase in serum gastrin and a non -
significant increase in the melatonin level.
Table 4 illustrates that treatment with melatonin and
omeprazole for 4 and 8 weeks leads to marked improve-
ment of GERD symptoms regarding heartburn and epi-
gastric pain. A significant increase in the tone of the
LES in the form of increased LES pressure also noted.
In addition, there is a significant increase in the residual
pressure, a significant decrease in the relaxation dura-
tion, a significant increase in the relaxation percentage,
a significant increase in the pH with a significant
decreased in BAO and a significant increase in serum
gastrin and melatonin levels.
Table 5 illustrates that treatment with melatonin alone
or combined with omeprazole (Group II & IV) leads to
a significant increase in the tone of the LES in the form
of increased LES pressure. Also, there is a significant
increase in the residual pressure, a significant decrease
in the relaxation duration, a significant increase in the
relaxation percentage compared with patients treated
Table 1 Comparison of control subjects and patients pretreated with melatonin, omeprazole and both (n = 9)
control Pretreatment with
melatonin
Pretreatment with
omeprazole
Pretreatment with melatonin and
omeprazole
Symptoms:
1-Heart burn:
Yes 07 7 8
Duration(months) 1.3 ± 0.4 1.2 ± 0.3 1.4 ± 0.4
2-Epigastric pain:
Yes 06 6 6
Duration(months) 1.4 ± 0.5 1.3 ± 0.4 1.3 ± 0.4
A)LES Study:
1-LES pressure(mmHg) 22.8 ±
1.3
10 ± 1.58
a 10.5 ± 2.86
a 10.3 ± 1.68
a
2-Residual pressure (mmHg) 0.4 ±
0.01
0.012 ± 0.52
a 0.1 ± 0.064
a 0.012 ± 0.44
a
3-Relaxation duration (seconds) 5.0 ± 0.1 6.8 ± 0.12
a 6.5 ± 2.74
a 6.8 ± 0.16
a
4-Relaxation % 100 ±
0.00
86 ± 0.87
a 87.2 ± 0.17
a 85 ± 1.58
a
C) PH (at 5 cm above the LES): 7.8 ± 0.4 2.3 ± 0.36
a 2.1 ± 0.38
a 1.98 ± 0.37
a
D) BAO (mmol/h) 2.6 ± 0.6 24.7 ± 0.5
a 25.1 ± 0.6
a 24.9 ± 0.7
a
E) Serum Gastrin(pg/ml) 41.8 ±
7.1
22.1 ± 4.2
a 21.5 ± 4.6
a 21.9 ± 4.7
a
D) Melatonin level at day time
(pg/ml):
36.1 ±
2.3
18.2 ± 5.54
a 18.5 ± 3.75
a 18.3 ± 3.8
a
a: p < 0.05 relative to control
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with omeprazole alone or combined with melatonin
(group III & IV) showed a significant increase in PH
and serum gastrin level with a significant decrease in
BAO than melatonin alone (group II)
Discussion
Melatonin, a close derivative of serotonin (5-hydroxy-
tryptamine, 5-HT) [13], is a hormone initiating sleep in
humans [14] and a powerful scavenger of free radicals.
It is more effective than several well-known vitamins
[15]. The pineal gland is the major source of melatonin
in the peripheral circulation, producing melatonin in a
distinct circadian fashion, with peak levels occurring
during the night [13]. Melatonin has been also detected
in entero-endocrine (EE) cells of gastro-intestinal tract
(GIT) wall, where this indole may act via endocrine,
paracrine and/or luminal pathway through G-protein
Table 2 Effects of melatonin on patients with GERD group II (n = 9)
Pretreatment with
melatonin
4 weeks Post treatment with
melatonin
8 weeks Post treatment with
melatonin
Symptoms:
1-Heart burn:
Yes 7 3 (57.1%) 0 (100%)
Duration(months) 1.3 ± 0.4
2-Epigastric pain:
Yes 6 3 (50%) 1 (83%)
Duration(months) 1.4 ± 0.5
B)LES Study:
1-LES pressure(mmHg) 10 ± 1.58 14.5 ± 1.58
a 20.2 ± 1.56
ab
2-Residual pressure (mmHg) 0.012 ± 0.52 0.2 ± 0.016 0.32 ± 0.013
a
3-Relaxation duration (seconds) 6.8 ± 0.12 5.9 ± 0.16
a 5.3 ± 0.12
a
4-Relaxation % 86 ± 0.87 90 ± 0.86
a 100 ± 0.00
ab
C) PH (at 5 cm above the LES): 2.3 ± 0.36 5.2 ± 0.5
a 6.7 ± 0.65
ab
D) BAO (mmol/h) 24.7 ± 0.5 20.1 ± 0.4
a 16.6 ± 0.6
ab
E) Serum Gastrin(pg/ml) 22.1 ± 3.2 27.2 ± 2.3
a 32.3 ± 2.1
ab
D) Melatonin level at day time (pg/
ml):
18.2 ± 5.54 28.26 ± 2.26
a 34.5 ± 2.35
ab
a: p < 0.05 relative to pretreatment with melatonin
b: p < 0.05 relative to 4 weeks post treatment with melatonin
Table 3 Effects of omeprazole on patients with GERD Group III (n = 9)
Pretreatment with
omeprazole
4 weeks Post treatment with
omeprazole
8 weeks Post treatment with
omeprazole
A) Symptoms:
1-Heart burn:
Yes 7 2 (71.4%) 0 (100%)
Duration(months) 1.2 ± 0.3
2-Epigastric pain:
Yes 62 0
Duration(months) 1.3 ± 0.4 (66.7%) (100%)
B)LES Study:
1-LES pressure(mmHg) 10.5 ± 2.86 10.4 ± 4.05 10.5 ± 2.85
2-Residual pressure (mmHg) 0.1 ± 0.064 0.2 ± 0.15 0.1 ± 0.07
3-Relaxation duration (seconds) 6.5 ± 2.74 6.3 ± 2.7 6.3 ± 2.65
4-Relaxation % 87.2 ± 0.17 87.3 ± 0.25 87.1 ± 0.1
C) PH (at 5 cm above the LES): 2.1 ± 0.38 5.9 ± 0.48
a 7.2 ± 0.32
ab
D) BAO (mmol/h) 25.1 ± 0.6 17.2 ± 0.7
a 11.5 ± 0.6
ab
E) Serum Gastrin (pg/ml) 21.5 ± 4.6 32.1 ± 2.1
a 35.9 ± 1.8
ab
D) Melatonin level at day time
(pg/ml):
18.5 ± 3.75 19.2 ± 3.47 17.9 ± 3.72
a: p < 0.05 relative to pretreatment with melatonin
b: p < 0.05 relative to 4 weeks Post treatment with melatonin
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light/dark cycle of plasma melatonin levels disappears,
while its daytime blood concentrations are attenuated
but sustained mainly due to its release from the GIT,
and therefore, a part of blood melatonin has a source in
the digestive system, especially during daytime [17].
In the present study, the mean melatonin level was
significantly lower in all patients in comparison to con-
trol group at baseline evaluation. This observation is in
agreement with Klupiñska et al [18] who found that in
patients with GERD and recurrent duodenal ulcers, mel-
atonin concentration was lower than in healthy subjects
and concluded that high or relatively correct secretion
of melatonin is sufficient to prevent peptic changes in
esophageal and duodenal mucosa. In addition, Bubenik
et al. [19] demonstrated that pigs with chronic gastric
ulcers exhibited lower contents of melatonin in the gas-
tric mucosa and in the blood suggesting that these
spontaneous ulcers originate from the local deficiency of
the indole.
However, Otsuka et al. [20] reported that acute stress
induced gastric lesions in rats are accompanied by
increased plasma melatonin. The proposed explanation
for the rise in melatonin is that its production increases
under stressful stimuli in both, experimental animals
and human as suggested by Karasek and Winczyk [21].
For the clinical purposes, some investigators measure
serum concentration of melat o n i nt w i c e ,t h a ti sa t9 . 0 0
a.m. (light period) and 2.00 a.m. (dark period) and the
differences in the day/night patterns taken for evaluation
[22]. The interests of gstroenterologists mainly focused
on studies on melatonin nocturnal secretion. In other
investigations, melatonin concentration in blood mea-
sured at three points of time: at 10.00 p.m., 2.00 a.m.
and 6.00 a.m. as done in our study as during these
hours the influence of food intake on enterohormones
secretion is negligible. On the other hand, at bedtime
the patients often complain of recurrent symptoms of
GERD that largely disturb their sleep [17]. It was also
noted that pharmacologically administered low and high
doses of melatonin have been found to be with very low
or no toxicity [23].
T h ec u r r e n ts t u d ya l s oe v a l u a t e st h er o l eo ft h e
recently used antiulcer drug melatonin, the widely used
antiulcer drug omeprazole and the combination of both
drugs in the treatment of GERD. We used an oral fast
release melatonin at a dose of 3 mg/day for 4 and 8
weeks. Werbach [24] found that melatonin up to 6 mg
at bedtime may be an effective treatment for GERD
with fewer and less serious adverse effects. It was found
that treatment of GERD with melatonin, omeprazole or
both was duration dependent. Patients treated with mel-
atonin for four weeks and patients treated with omepra-
zole for four weeks showed incomplete improvement of
GERD symptoms. These findings are in agreement with
Gavert and Harvey [25]. Moreover, in patients treated
Table 4 Effects of melatonin and omeprazole on patients with GERD group IV (n = 9)
Pretreatment with melatonin
and omeprazole
4 weeks Post treatment with
melatonin and omeprazole
Post 8 weeks treatment with
melatonin and omeprazole
A) Symptoms:
1-Heart burn:
Yes 8 1(87.5%) 0 (100%)
Duration(months) 1.4 ± 0.4
2-Epigastric pain:
Yes 6 1(83.3%) 0 (100%)
ration(months) 1.3 ± 0.4
B) LES Study:
1-LES pressure(mmHg) 10.3 ± 1.68 14.5 ± 1.26
a 20.5 ± 1.22
ab
2-Residual pressure
(mmHg)
0.012 ± 0.44 0.21 ± 0.016 0.33 ± 0.016
a
3-Relaxation duration
(seconds)
6.8 ± 0.16 5.8 ± 0.13
a 5.2 ± 0.12
a
4-Relaxation % 85 ± 1.58 90 ± 1.23
a 100 ± 0.00
ab
C) PH (at 5 cm above the
LES):
1.98 ± 0.37 6.1 ± 0.55
a 7.5 ± 0.31
ab
D) BAO (mmol/h) 24.9 ± 0.7 15.8 ± 0.9
a 10.2 ± 0.9
ab
E) Serum Gastrin (pg/ml) 21.9 ± 4.7 33.6 ± 2.7
a 36.8 ± 2.1
ab
D) Melatonin level at day
time (pg/ml):
18.3 ± 3.8 28.83 ± 1.82
a 34.5 ± 2.35
ab
a: p < 0.05 relative to pretreatment with melatonin
b: p < 0.05 relative to 4 weeks Post treatment with melatonin
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Melatonin Omeprazole Melatonin and Omeprazole P value
P1 P2 P3
A)Symptoms:
Heart burn:
control 0 0 0
pretreatment:
yes 7 7 8
duration (months) 1.3 ± 0.4 1.2 ± 0.3 1.4 ± 0.4
4 weeks
8 weeks 3(57.1%) 2(71.4%) 1(87.5%)
0(100%) 0(100%) 0(100%)
Epigastric pain:
-control 0 0 0
pretreatment:
yes 6 6 6
duration (months) 1.4 ± 0.5 1.3 ± 0.4 1.3 ± 0.4
4 weeks 3(50%) 2(66.7%) 1(83.3%)
8 weeks 1(83%) 0(100%) 0(100%)
B) LES Study: P1 P2 P3
1-LES pressure(mmHg)
control 22.8 ± 1.3 22.8 ± 1.3 22.8 ± 1.3 0.9 0.9 0.9
pretreatment: 10 ± 1.58 10.5 ± 2.86 10.3 ± 1.68 0.65 0.7 0.86
4 weeks 14.5 ± 1.58 10.4 ± 4.05 14.5 ± 1.26 0.006 0.468 0.002
8 weeks 20.2 ± 1.56 10.5 ± 2.85 20.5 ± 1.22 0.000 0.68 0.000
2-Residual pressure (mmHg) P1 P2 P3
- control 0.4 ± 0.01 0.4 ± 0.01 0.4 ± 0.01 1.0 1.0 1.0
pretreatment: 0.012 ± 0.52 0.1 ± 0.064 0.012 ± 0.44 0.578 1.00 0.556
4 weeks 0.2 ± 0.016 0.2 ± 0.15 0.21 ± 0.016 1.00 0.198 0.198
8 weeks 0.32 ± 0.013 0.1 ± 0.07 0.33 ± 0.016 0.000 0.08 0.000
3-Relaxation duration (seconds) P1 P2 P3
control 5.0 ± 0.1 5.0 ± 0.1 5.0 ± 0.1 1.0 1.0 1.0
pretreatment:: 6.8 ± 0.12 6.5 ± 2.74 6.8 ± 0.16 0.747 1.000 0.747
4 weeks 5.9 ± 0.16 6.3 ± 2.7 5.8 ± 0.13 0.662 0.153 0.585
8 weeks 5.3 ± 0.12 6.3 ± 2.65 5.2 ± 0.12 0.747 0.102 0.059
4-Relaxation % P1 P2 P3
control 100 ± 0.00 100 ± 0.00 100 ± 0.00 1.0 1.0 1.0
pretreatment: 86 ± 0.87 87.2 ± 0.17 85 ± 1.58 0.12 0.116 0.14
4 weeks 90 ± 0.86 87.3 ± 0.25 90 ± 1.23 0.1 1.000 0.1
8 weeks 100 ± 0.00 87.1 ± 0.1 100 ± 0.00 0.01 1.00 0.01
C) PH (at 5 cm above the LES): P1 P2 P3
control: 7.8 ± 0.4 7.8 ± 0.4 7.8 ± 0.4 1.0 1.0 1.0
pretreatment: 2.3 ± 0.36 2.1 ± 0.38 1.98 ± 0.37 0.1 0.1 0.1
4 weeks 5.2 ± 0.5 5.9 ± 0.48 6.1 ± 0.55 0.008 0.002 0.09
8 weeks 6.7 ± 0.65 7.2 ± 0.32 7.5 ± 0.31 0.01 0.008 0.1
D) BAO(mmol/h) P1 P2 P3
- control: 2.6 ± 0.6 2.6 ± 0.6 2.6 ± 0.6 1.0 1.0 1.0
pretreatment: 24.7 ± 0.5 25.1 ± 0.6 24.9 ± 0.7 0.1 0.1 0.1
4 weeks 20.1 ± 0.4 17.2 ± 0.7 15.8 ± 0.9 0.008 0.002 0.09
- 8 weeks 16.6 ± 0.6 11.5 ± 0.6 10.2 ± 0.9 0.01 0.008 0.1
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melatonin and omeprazole for four weeks, there was
complete improvement of GERD symptoms as heart-
burn and epigastric pain. These findings were in agree-
ment with Pereira [26] who reported that dietary
supplementation containing melatonin and L-trypto-
phan, which is a substrate for melatonin biosynthesis in
patients with GERD, resulted in remarkable remission of
GERD symptoms in the majority of treated patients.
The clinical remission of GERD was comparable with
that obtained by classical treatment using omeprazole. It
was concluded that the formulation containing melato-
nin or its precursor, tryptophan, promotes regression of
GERD symptoms without any side effects and may be
useful in the GERD therapy. Melatonin has also been
studied in alleviating GERD. In a head-to-head compari-
son, the researchers gave 175 patients standard treat-
ment with the prescription drug omeprazole, while 176
received a supplement containing melatonin, its precur-
sor L-tryptophan, and B vitamins, over a 40-day treat-
ment period. All patients in the supplement group
reported complete regression of symptoms by the end
of the study, compared with only 66% in the drug-trea-
ted group. Again, no significant side effects were
reported in the supplemented patients [26].
Although many studies were carried out to evaluate
the role of melatonin in GERD based on its effect in
alleviation of GERD symptoms only, the review of litera-
ture showed that no previous studies were based on
endoscopic findings besides the clinical improvement.
In the present study, also signs were improved includ-
ing lower esophageal sphincter (LES) pressure (from 10
± 1.58 and, 10.3 ± 1.68 mmHg in the pretreated patients
to 16.5 ± 0.6, and 14.1 ± 0.5 mmHg in patients treated
with melatonin for 8 weeks and patients treated with
melatonin and omeprazole for 4 weeks respectively). In
addition, residual pressure (from 0.012 ± 0.52, and,
0.012 ± 0.44 in the pretreated patients to 0.32 ± 0.013,
and, 0.21 ± 0.016 mmHg patients treated with
melatonin for 8 weeks and patients treated with melato-
nin and omeprazole for 4 weeks respectively). Besides,
relaxation duration (from 6.8 ± 0.12, and 6.8 ± 0.16 sec-
onds in the pretreated patients to 5.3 ± 0.12, and 5.8 ±
0.13 seconds in patients treated with melatonin for 8
weeks and patients treated with melatonin and omepra-
zole for 4 weeks respectively), relaxation % (from 86 ±
0.87, and 85 ± 1.58% in pretreated patients to 95 ± 0.9
and 90 ± 1.23% in patients treated with melatonin for 8
weeks and patients treated with melatonin and omepra-
zole for 4 weeks respectively). However, the pH, 5 cm
above the level of LES, was elevated from 2.3 ± 0.36, 2.1
± 0.38 and 1.98 ± 0.37 in pretreated patients to 5.9 ±
0.65, 5.9 ± 0.48 and 6.1 ± 0.55 in patients treated with
melatonin for 8 weeks, patients treated with omeprazole
for 4 weeks and patients treated with melatonin and
omeprazole for 4 weeks respectively).
It was believed that melatonin protects against GERD
by increasing blood flow and anti-inflammatory mole-
cules in the esophageal mucous, thus preventing signifi-
cant esophageal injury [27]. Although, Sener-Muratoglu
et al. [28] previously compared the antiulcer and gastro
duodenal protective mechanism of famotidine, omepra-
zole and melatonin and their results revealed that the
three drugs have gastroduodenal protective action but
famotidine and omeprazole have lowering effects on gas-
tric acidity (antisecrotory activity) whereas melatonin has
no effect on this parameter but famotidine and omepra-
zole were not efficient as antioxidant as melatonin.
However, others concluded that the esophagoprotec-
tive activity of melatonin against GERD might be related
to the inhibitory effect of this indole on gastric acid
secretion and due to stimulation of gastrin release,
which might attenuate the gastro-esophageal reflux by
stimulation of the contractile activity of the lower eso-
phageal sphincter [29].
In the present study, there was a significant increase
in the pH with a significant decrease in BAO and a sig-
nificant increase in serum gastrin after melatonin
Table 5: Comparison of the three treated groups with GERD (Continued)
E) Serum Gastrin(pg/ml) P1 P2 P3
control: 41.8 ± 7.1 41.8 ± 7.1 41.8 ± 7.1 1.0 1.0 1.0
pretreatment: 22.1 ± 4.2 21.5 ± 4.6 21.9 ± 4.7 0.1 0.1 0.1
4 weeks 27.2 ± 2.3 32.1 ± 2.1 33.6 ± 2.7 0.008 0.002 0.09
- 8 weeks 32.3 ± 2.1 35.9 ± 1.8 36.8 ± 2.1 0.01 0.008 0.1
D) Melatonin level at day time (pg/ml): P1 P2 P3
control 36.1 ± 2.3 36.1 ± 2.3 36.1 ± 2.3 1.0 1.0 1.0
pretreatment: 18.2 ± 5.54 18.5 ± 3.75 18.3 ± 3.8 0.1 0.665 0.472
4 weeks 28.26 ± 2.26 19.2 ± 3.47 28.83 ± 1.82 0.000 0.55 0.000
8 weeks 34.5 ± .35 17.9 ± 3.72 34.5 ± 2.35 0.000 1.00 0.000
P1: group III versus group II
P2: group IV versus group II
P3: group IV versus group III
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Page 7 of 9therapy compared to pretreatment levels. While patients
treated with omeprazole alone or combined with mela-
tonin showed a significant increase in PH and serum
gastrin level with a significant decrease in BAO than
melatonin alone, however, the combined therapy
showed a non-significant increase in serum gastrin or
BAO compared with omeprazole alone.
These protective effects were accompanied by gradual
increase in plasma melatonin levels suggesting that topi-
cal melatonin exerts a local protective action on gastric
mucosa, acting via circulation following its absorption
form the gut. The results of our study revealed that mela-
tonin has a role in the improvement of GERD as detected
in patients treated with melatonin for 8 weeks and in
patients treated with melatonin and omeprazole for 4
weeks. Meanwhile, omeprazole alone has a better effect
on gastric acidity than melatonin alone as the clinical
improvement started at the fourth week of treatment
with omeprazole and was completed at the eighth week.
On the other hand, with melatonin alone the improve-
ment started at the fourth week and was completed at
the eighth week of treatment but it was significantly less
effective than omeprazole. It was found that melatonin
accelerates the clinical and endoscopic improvement
when combined with omeprazole as improvement in
combination therapy was completed at shorter duration
(at the fourth week) with no further increase in serum
gastrin level. Our results were in agreement with Bandyo-
padhyay et al. [30] who stated that melatonin prevented
gastric damage and when compared with already mar-
keted anti-ulcer drugs such as ranitidine and omeprazole,
melatonin was found to be more effective than ranitidine
but less effective than omeprazole in preventing stress
ulcer. They also demonstrated that co-treatment of
GERD with melatonin at a low dose synergistically
increases the efficacy of omeprazole in preventing stress
induced lesion. This may be important, as giving omepra-
zole at lower doses would reduce the severity of their side
effects. Rieter et al. [31] reported that melatonin when
combined with other anti ulcer drugs like omeprazole
has a beneficial effect as it accelerates the healing effects
of omeprazole and shortens the duration of treatment.
Therefore, melatonin reduces the side effects and
increases the efficacy of omeprazole.
Conclusion
From the results of our study, it can be concluded that
melatonin could be used in the treatment of GERD
either alone or in combination with omeprazole. The
combination therapy of both melatonin and omeprazole
is preferable as melatonin accelerates the healing effect
of omeprazole and therefore shortens the duration of
treatment and minimizes its side effects.
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